转移性肾细胞癌一线系统治疗:系统综述与网络荟萃分析
该研究通过系统综述与网络荟萃分析间接比较转移性肾细胞癌一线系统治疗的疗效与安全性。结果显示卡博替尼在无进展生存期方面可能性最高(SUCRA 91%),纳武利尤单抗联合伊匹木单抗在总生存期和不良反应耐受性方面可能性最高。
要点
- 卡博替尼在无进展生存期方面可能性最高(SUCRA 91%)。
- 纳武利尤单抗联合伊匹木单抗在总生存期方面有48%可能性为优选。
- 纳武利尤单抗联合伊匹木单抗在不良反应方面有67%可能性为耐受性最佳方案。
核心结论
- 卡博替尼和纳武利尤单抗联合伊匹木单抗可能是转移性肾细胞癌一线治疗的优选药物,但需要直接比较研究验证。
研究设计与样本
- 系统综述检索Medline、EMBASE、Web of Science和Scopus数据库(建库至2017年10月23日),纳入平行组随机对照试验。
主要发现
- 无进展生存期分析(10项试验,4819例患者)显示卡博替尼为优选治疗的可能性高(SUCRA 91%)。
- 总生存期分析(5项试验,3379例患者)显示纳武利尤单抗联合伊匹木单抗为优选方案的可能性为48%。
- 不良反应方面纳武利尤单抗联合伊匹木单抗为耐受性最佳方案的可能性为67%。
临床怎么用
- 研究结果可为患者和临床医生在转移性肾细胞癌一线治疗决策时提供参考。
- 研究结果可能有助于指导未来直接比较试验的设计。
局限性
- 大多数药物缺乏直接比较数据,结论基于间接比较。
- 需要直接比较研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: In the last decade, there has been a proliferation of treatment options for metastatic renal cell carcinoma (mRCC). However, direct comparative data are lacking for most of these agents. OBJECTIVE: To indirectly compare the efficacy and safety of systemic therapies used in the first-line treatment of mRCC. EVIDENCE ACQUISITION: Medline, EMBASE, Web of Science, and Scopus databases were searched using the OvidSP platform for studies indexed from database inception to October 23, 2017. Abstracts of conferences of relevant medical societies were included, and the systematic search was supplemented by hand search. For the systematic review, we identified any parallel-group randomized controlled trials assessing first-line systemic therapy. For network meta-analysis, we limited these to a clinically-relevant network based on standard practice patterns. Progression-free survival (PFS) was the primary outcome. Overall survival (OS) and grade 3 and 4 adverse events (AEs) were secondary outcomes. EVIDENCE SYNTHESIS: In total, 37 trials reporting on 13 128 patients were included in the systematic review. The network meta-analysis comprised 10 trials reporting on 4819 patients. For PFS (10 trials, 4819 patients), there was a high likelihood (SUCRA 91%) that cabozantinib was the preferred treatment. For OS (5 trials, 3379 patients), there was a 48% chance that nivolumab plus ipilimumab was the preferred option. There was a 67% likelihood that nivolumab plus ipilimumab was the best tolerated regime with respect to AEs. CONCLUSIONS: Cabozantinib and nivolumab plus ipilimumab are likely to be the preferred first-line agents for treating mRCC; however, direct comparative studies are warranted. These findings may provide guidance to patients and clinicians when making treatment decisions and may help inform future direct comparative trials. PATIENT SUMMARY: There are many treatment options for patients diagnosed with metastatic renal cell carcinoma. We indirectly compared the available options and found that cabozantinib and nivolumab plus ipilimumab are likely to be preferable choices as the first-line treatment in this situation.
引用
- Wallis CJD, Klaassen Z, Bhindi B, et al. First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. Eur Urol. 2018. PMID: 29656851. doi:10.1016/j.eururo.2018.03.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。